期刊文献+

晚期卵巢上皮癌化疗的用药剂量 被引量:4

下载PDF
导出
摘要 探讨药物总剂量(CD)、剂量强度(DI)、剂量密度对晚期卵巢上皮癌化疗的疗效。单纯延长化疗疗程数、提高化疗CD不会改善预后。同时增加顺铂DI和CD可能延长存活时间,尤其对残留小病灶者。紫杉醇及卡铂DI对预后影响不大。化疗间隔缩短1~2周称为剂量密度,一般称为周疗。紫杉醇周疗多用于二或三线化疗,疗效很好。顺铂周疗可用于残留小病灶的一及二、三线化疗。在保证最基本剂量基础上增加CD和DI或应用剂量密度化疗可能会改善预后。
作者 赵晓东 张毅
机构地区 北京医院妇产科
出处 《国外医学(妇产科学分册)》 2005年第4期235-238,共4页 Foreign Medical Sciences(Obstet Gynecol Fascicle)
  • 相关文献

参考文献18

  • 1Gore M, Mainwaring P, A'Hem R, et al. Randomized trim of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol,1998,16(7):2426-2434.
  • 2Jackobsen A, Bertelsen K, Andersen JE,et al. Dose-effect study of carboplatin in ovarian cancer: a Danish ovarian cancer Group Study.J Clin Ocol,1997,15(1):193-198.
  • 3Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol, 1996, 14(7): 2113-2119.
  • 4Conte PF, Bruzzone M, Carnino F, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer:. A randomized study of the gono. J Clin Oncol, 1996, 14(2): 351-356.
  • 5Dittrich CH, Sevelda P, Salzer H, et al. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase Ⅲ study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.Eur J Cancer,2003,39(8):1129-1140.
  • 6Joly F, Heron JF, Kerbrat P, et al. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC). Gynecol Oncol, 2000,78(3 pt 1):361-368.
  • 7Gumey H. How to calculate the dose of chemotherapy. Br J Cancer,2002, 86(8): 1297-1302.
  • 8Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Aeta Oneol, 2002,41(5):418-424.
  • 9Watanabe Y, Nakai H, Ueda H, et al. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer. Gynecol Oncol,2005 ,96(2):323-329.
  • 10Garcia AA, O'Meara A, Bahador A, et al. Phase Ⅱ study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol, 2004,93(2):493-498.

同被引文献26

  • 1成夜霞,冯捷,刘晨,白符,杨蓉.Ⅲ期浆液性卵巢癌存活及复发相关因素分析[J].中国妇产科临床杂志,2004,5(4):281-285. 被引量:6
  • 2张树荣,李荷莲,乐杰.卵巢癌耐药机制研究进展[J].实用妇产科杂志,2006,22(3):148-150. 被引量:14
  • 3康映蕖.卵巢恶性肿瘤的防治进展[J].中华妇产科杂志,1979,14(1):54-59.
  • 4孙爱达 连利娟 等.晚期与复发性卵巢上皮癌的手术治疗[J].中华妇产科杂志,1987,22(6):344-346.
  • 5Mylona E, Alexandrou P, Mpakali A, et al. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma[J]. Eur J Surg Oncol, 2007, 33(3): 294-300.
  • 6Herrmann E, Ehze E, Bierer S, et al. VEGF-C, VEGF-D and Fit-4in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival[J]. Anticancer Res, 2007, 27(5A): 3127-3133.
  • 7Ueda M, Hung YC, Terai Y, et al. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas[J]. CIin Cancer Res, 2005, 11(9): 3225-3232.
  • 8Yokoyama Y, Charnrk-Jones DS, Licence D, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma[J]. Br J Cancer, 2003, 88(2): 237-244.
  • 9Le T, Alshaikh G, Hopkins L, et al. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking[J]. Ann Surg Oncol, 2006, 13( 12): 1711- 1716.
  • 10曹泽毅.中华妇产科学[M].北京:人民卫生出版社,1999.2129.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部